Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

FDA Approves Drug to Treat Parkinson’s Disease Psychosis

Today, the FDA approved Nuplazid (pimavanserin) as the first drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis, which affects up to 40% of people with Parkinson’s.

NPF’s National Medical Director, Dr. Michael S. Okun, says “Today’s approval of Nuplazid represents a major paradigm shift in the treatment of Parkinson’s disease psychosis. Through its novel and selective mechanism of action, Nuplazid is a breakthrough treatment that works in a whole new way -- treating hallucinations and delusions without blocking dopamine A chemical messenger (neurotransmitter) that regulates movement and emotions. receptors and, therefore, not impairing motor function in Parkinson’s psychosis patients.”

What Does this Mean for the Parkinson’s Community?

Before this approval, there was no FDA-approved drug for the treatment of psychosis A broad medical term used to describe a loss of contact with reality that involves hallucinations and/or delusions. in Parkinson’s. Expert neurologists and psychiatrists had to choose between one of several atypical antipsychotic medications that were not proven effective in Parkinson’s or one that had been proven effective but had a fairly negative safety profile and required patients to take weekly blood tests to make sure that they were tolerating the drug well.

Additionally, many antipsychotic drugs work by blocking dopamine. Since Parkinson’s is a disease where dopamine producing neurons are lost, blocking dopamine is bad – we think that sometimes it is fatal. With FDA approval, we can hope that most patients with Parkinson’s will have access to a drug designed just for them and for Parkinson’s.

Like any powerful drug, there are risks associated with Nuplazid. We encourage you to be careful and talk with your neurologist about all options.

What Does this Mean for Parkinson’s Research?

We hope the approval of Nuplazid will inspire others to aggressively pursue novel therapies for Parkinson’s. We hope this approval will lead to better outcomes for people with Parkinson’s today and inspire the next breakthrough.

Questions about Parkinson’s disease psychosis? Learn more or call our free Helpline at 1-800-4PD-INFO (473-4636).

Questions about Nuplazid? Visit www.nuplazid.com or call 1-844-737-2223.

Friday, April 29, 2016
Parkinson’s Foundation Earns 4-Star Rating from Charity Navigator
Monday, October 22, 2018

NEW YORK AND MIAMI—October 22, 2018—The Parkinson’s Foundation has achieved a 4-star rating from Charity Navigator, the nation's largest and most-utilized evaluator of charities.

The 4-star rating is the highest rating given only to nonprofit organizations that exceed industry standards and outperform peers, while demonstrating strong financial health and commitment to accountability and transparency.

Parkinson’s Foundation Awards New Nurse Faculty Grant to Four Nurses Specializing in Parkinson’s Care
Thursday, October 11, 2018

NEW YORK & MIAMI — October 11, 2018 — The Parkinson’s Foundation announced that it has awarded its first-ever Parkinson’s Foundation Nurse Faculty Award to four nurses, totaling $30,000. The nurses, all graduates of the Edmond J.

Update on NUPLAZID — FDA finds no new or unexpected safety risks
Friday, September 21, 2018

On September 20, 2018, the U.S.

Parkinson’s Foundation Extends Bilingual National Helpline Hours
Tuesday, September 18, 2018

NEW YORK & MIAMI — September 18, 2018 — The Parkinson’s Foundation announced today that its toll-free Helpline, 1-800-4PD-INFO, will extend its hours, answering calls in English and Spanish, to help make life better for people with Parkinson’s disease (PD) and their families.

Parkinson’s Foundation Hosts Allied Team Training for Parkinson’s in Atlanta
Tuesday, September 11, 2018

NEW YORK & MIAMI—September 11, 2018—The Parkinson’s Foundation today announced the location of its signature professional education program course, Allied Team Training for Parkinson’s, ATTP®, for health care professionals treating patients with Parkinson’s disease, in Atlanta.

Parkinson’s Foundation Increases Funding to $6.2 Million to Advance Parkinson’s Research
Tuesday, August 14, 2018

NEW YORK & MIAMI — August 14, 2018 — The Parkinson’s Foundation announced today an increased investment of $6.2 million across 53 research grants to support the work of promising scientists in the field of Parkinson's disease (PD) in 2018.

PD Gladiators Merges with the Parkinson’s Foundation Expanding Reach in Greater Atlanta Parkinson’s Community
Wednesday, August 1, 2018

ATLANTA – August 1, 2018—PD Gladiators, Inc., an Atlanta-based nonprofit organization focused on combatting Parkinson’s disease (PD) with vigorous exercise, has merged with the Parkinson’s Foundation (PF), a non-profit organization whose mission is to make life better for people with PD worldwide through expert care and research.

Parkinson’s Foundation Partners with Medscape Education to Deliver Patient Education
Monday, July 30, 2018

July 30, 2018—The Parkinson’s Foundation has collaborated with Medscape Education to launch an online learning program entitled “Parkinson’s Disease Psychosis: A Learning Destination for Care Partners and Patients,” available on Medscape’s patient portal, WebMD Education.

Parkinson’s Foundation Designates Three Centers of Excellence in Parkinson’s Care: Global Network Expands to 45 Parkinson’s Centers
Tuesday, July 24, 2018

MIAMI & NEW YORK CITY — July 24, 2018 — The Parkinson’s Foundation today announced the addition of three new Centers of Excellence to its global network: Cleveland Clinic; Medical University of South Carolina; and University of Iowa Hospitals and Clinics.

Parkinson’s Foundation Funds $450,000 for Local Parkinson’s Programs in Seven Cities Across the Country
Monday, July 23, 2018

NEW YORK & MIAMI — July 23, 2018 — The Parkinson's Foundation today announced it will fund nearly $450,000 to local community grants in seven cities that hosted the Foundation's annual fundraiser, Moving Day, A Walk for Parkinson's, in 2017. These grants will further the health, wellness and education of people with Parkinson's disease (PD).

Pages

mail icon

Subscribe here to get the latest news on treatments, research and other updates.